This is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.
The subject voluntarily signs the informed consent form (ICF).
Aged 18-70 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Serum M-protein ≥1.0 g/dL
Concurrent plasma cell leukemia, central nervous system involvement, or amyloidosis.
Peripheral neuropathy of Grade >1, or Grade 1 peripheral neuropathy with pain. Prior or ongoing systemic therapy or stem cell transplantation for symptomatic multiple myeloma, except for the emergency use of a short course of corticosteroids equivalent to dexamethasone 40 mg/day for 4 days, provided that the course is completed within 14 days before randomization.
Any contraindication to, or a history of life-threatening allergy, hypersensitivity, or intolerance to, any study drug or its excipients.
Pregnant or breastfeeding, or planning to become pregnant during participation in the study or within 6 months after the last dose of any study treatment.
Single group
anti-BCMA/CD3 bispecific antibody
DrugAnti-BCMA/CD3 bispecific antibody (Elranatamab) will be administered via a subcutaneous injection (SC).
Minimal residual disease (MRD) negativity rate
Adverse events and serious adverse events
Sustained MRD negativity rate
Overall response rate (ORR)
Complete response rate (CR)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
